Biogen pays $200mm up front for Convergence, plus earn-outs
Enhancing its pain portfolio, Biogen Idec Inc. acquired closely held UK biotech Convergence Pharmaceuticals Ltd. for $200mm in cash up front plus up to $475mm in earn-outs.
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com